Clinical Trial Update: A Study of the Safety and Efficacy Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis (IPF) [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the safety and efficacy of interferon-gamma 1b in idiopathic pulmonary fibrosis has completed, with InterMune as sponsor.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• Interferon-gamma 1b (interferon gamma-1b)

Snippet

Sponsor: InterMune | Conditions: Idiopathic Pulmonary Fibrosis | Phase 3 | Status: COMPLETED